<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777127</url>
  </required_header>
  <id_info>
    <org_study_id>X-03016-3271</org_study_id>
    <secondary_id>2007-004884-24</secondary_id>
    <nct_id>NCT00777127</nct_id>
  </id_info>
  <brief_title>Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses</brief_title>
  <acronym>LEIDA</acronym>
  <official_title>Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (LEIDA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MEDA Pharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MEDA Pharma GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial serves the purpose to compare the long-term effects of a treatment of
      actinic keratosis - your skin disorder - using Aldara® 5% cream or Solaraze® 3% gel on the
      face or the scalp. In particular, it should be found out whether the healing effect of these
      two medications on the skin lesions (i.e. the damaged skin parts) can be maintained for a
      prolonged period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence with respect to the study treatment area until month 12</measure>
    <time_frame>week 20 until month 12</time_frame>
    <description>A patient is classified as recurrent when cleared at Visit Week 20 and having later on at least one clinically diagnosed AK lesion in the study treatment area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term outcome with respect to development of SCC (in situ and/or invasive)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of rescue treatment</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematological changes</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcome.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aldara 5% Cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Solaraze 3% Gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <description>One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Immunocompetent patient.

          -  A study treatment area must be identifiable: Minimum of 5 and maximum of 10 typical
             visible AKs in one contiguous area of up to 50 cm2 on the face or scalp. The eyelids,
             the inside of the nostrils or ears, or the lip area inside the vermilion border must
             not be part of this area.

          -  A positive histological finding for AK grade I or II (see Section 7.1.1.2). This will
             be determined from the most suspicious lesion in the STA and there from the most
             pathological area biopsied during screening visit. This analysis will be done by the
             central histopathological laboratory.

          -  Willingness to comply with the obligations of the study.

        Exclusion Criteria:

        Safety concerns:

          -  History of allergic reaction to imiquimod, diclofenac, acetyl salicylic acid, other
             non steroidal anti-inflammatory drugs (NSAID), hyaluronic acid, or relevant
             excipients.

          -  Pregnancy, breast-feeding or planned pregnancy during the study. Women of child
             bearing potential not using a highly effective method of birth control defined as
             those which result in a low failure rate (i.e. &lt;1% per year) when used consistently
             and correctly such as implants, injectables, combined oral contraceptives, hormonal
             IUDs, tubal ligation or vasectomised partner.

        Lack of suitability for the study:

          -  Presence of AK lesions in the STA with clinically marked hyperkeratosis or hypertrophy
             as seen in cutaneous horns.

          -  Any topical AK treatment including imiquimod or diclofenac, or any systemic AK
             treatment such as systemic retinoids, or any surgical AK treatment at the STA within
             the last 2 months prior to randomisation.

          -  Persisting AK lesion at screening visit following topical treatment with imiquimod or
             diclofenac in the STA.

          -  Topical treatment with imiquimod or diclofenac anywhere else on the body within the
             last 2 months prior to randomisation.

          -  Presence of any histologically confirmed skin tumour in the STA: in situ SCC including
             Bowen's disease, invasive SCC, basal cell carcinoma, or other malignant tumours.

          -  Any dermatological disease or condition that may exacerbate by treatment with
             imiquimod or diclofenac (e.g. rosacea, psoriasis, atopic dermatitis).

          -  Any dermatological disease or condition in the STA that causes difficulty with
             examination (e.g. eczema).

          -  Systemic immunomodulatory treatment such as interferon, azathioprine, cyclosporine,
             retinoids, any oral or injectable corticosteroids, or inhaled or nasal corticosteroids
             with dosages of &gt;1200 µg/day beclomethasone or equivalent within 4 weeks before start
             of study treatment.

          -  History of any malignant tumour with high tumour burden or any systemic antitumour
             treatment (incl. radiotherapy).

          -  History of any malignant skin tumour having metastasised or where metastasis could be
             expected.

          -  History of severe cardiovascular, pulmonary, hepatic, renal, gastrointestinal,
             haematological, endocrine, metabolic, mental, neurological, or other disease within
             the last two years.

          -  Mentally incapacitated patient.

          -  Present or history of drug or alcohol abuse within the last 3 years.

        Administrative reasons:

          -  Exposure to an investigational product within the last 3 months.

          -  Lack of ability or willingness to give informed consent.

          -  Age below 18 years.

          -  Lack of willingness to have personal study related data collected, archived or
             transmitted according to protocol.

          -  Anticipated non-availability for study visits/procedures.

          -  Vulnerable subjects (such as persons kept in detention).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Gollnick, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Otto-von-Guericke-University of Magdeburg/Germany, Clinic for Dermatology and Venereology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ursula Petzold, PhD</last_name>
    <role>Study Director</role>
    <affiliation>MEDA Pharma GmbH &amp; Co. KG, Bad Homburg/Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Feldkirch, Department for Dermatology and Venereology</name>
      <address>
        <city>Feldkirch</city>
        <zip>A-6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Graz, University Clinic for Dermatology and Venereology</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck, University Clinic for Dermatology and Venereology</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna, Department for General Dermatology</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St Jacques, Department for Dermatology</name>
      <address>
        <city>Besancon Cedex</city>
        <zip>F-25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sainte Marguerite, Department for Dermatology and Venereology, Pavilion 3, First Floor</name>
      <address>
        <city>Marseille</city>
        <zip>F-13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice - Hospital Archet 2, Department for Dermatology</name>
      <address>
        <city>Nice</city>
        <zip>F-06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Saint-Louis, Derpartment for Dermatology</name>
      <address>
        <city>Paris</city>
        <zip>F-75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Center Lyon South, Department for Dermatology and Immuno-Allergology</name>
      <address>
        <city>Pierre Benite</city>
        <zip>F-69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Licca Clinical Research Institute</name>
      <address>
        <city>Augsburg</city>
        <zip>D-86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Medicine University Berlin, Dermatoma Center, Clinic for Dermatology, Allergology and Venereology</name>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Practice Dominicus / Bockhorst</name>
      <address>
        <city>Duelmen</city>
        <zip>D-48249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical practice</name>
      <address>
        <city>Düsseldorf</city>
        <zip>D-40210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Düsseldorf, Clinic for Dermatology</name>
      <address>
        <city>Düsseldorf</city>
        <zip>D-40255</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic and Medical Faculty of Johann Wolfgang Goethe-University, Center for Dermatology and Venereology</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCiderm GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Practice</name>
      <address>
        <city>Hannover</city>
        <zip>D-30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Schleswig-Holstein, Campus Kiel, Clinic for Dermatology, Venereology and Allergology</name>
      <address>
        <city>Kiel</city>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Department of Otto-von-Guericke-University Magdeburg, University Clinic for Dermatology and Venereology</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology J. Gutenberg-University Mainz, Clinical Research Center</name>
      <address>
        <city>Mainz</city>
        <zip>D-55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Science, Onco &amp; Beauty GbR, Practice for Dermatology and Medical Cosmetics</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>D-41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Münster, Clinic and Polyclinic for Skin Diseases</name>
      <address>
        <city>Münster</city>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic University Regensburg, Clinic and Polyclinic for Dermatology</name>
      <address>
        <city>Regensburg</city>
        <zip>D-93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derma Center Vechta</name>
      <address>
        <city>Vechta</city>
        <zip>D-49377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrovital</name>
      <address>
        <city>Witten</city>
        <zip>D-58453</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical practice for Dermatology and Venerology</name>
      <address>
        <city>Wuppertal</city>
        <zip>D-42275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.euroderm.org</url>
    <description>European Dermatology Forum, Guidelines for the management of actinic keratoses. Last modified 26 Ocotober 2006.</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <last_update_submitted>January 31, 2013</last_update_submitted>
  <last_update_submitted_qc>January 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>actinic keratosis</keyword>
  <keyword>invasive SCC</keyword>
  <keyword>in situ SCC</keyword>
  <keyword>histological classification</keyword>
  <keyword>histological progression</keyword>
  <keyword>clinical clearance</keyword>
  <keyword>cryotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

